What is A-Alpha Bio?
A-Alpha Bio is at the forefront of biotechnology innovation, specializing in the discovery of potentially therapeutic proteins. By integrating advanced computational methodologies with precise yeast-based experimental techniques, the Seattle-based company aims to accelerate the identification and development of novel protein-based therapeutics. This unique combination of computational power and biological experimentation positions A-Alpha Bio to address complex diseases and unmet medical needs within the pharmaceutical landscape.
How much funding has A-Alpha Bio raised?
A-Alpha Bio has raised a total of $68.3M across 3 funding rounds:
Angel/Seed
$2.8M
Series A
$51M
Other Financing Round
$14.5M
Angel/Seed (2019): $2.8M with participation from biotech angel investors, Boom Capital, Madrona Venture Group, Sahsen Ventures, OS Fund, AME Cloud Ventures, and Washington Research Foundation
Series A (2023): $51M led by Perceptive Advisors, Lux Capital, Perceptive Xontogeny Ventures, and Madrona Venture Group
Other Financing Round (2024): $14.5M supported by U.S. Department of Defense
Key Investors in A-Alpha Bio
Perceptive Advisors
Perceptive Advisors is an investment firm established in 1999, managing approximately $7 billion in assets and specializing in funding innovative healthcare and life sciences technologies.
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, including biotechnology, from seed through IPO.
Madrona Venture Group
Founded in 1995, Madrona Venture Group is a venture capital firm that invests in companies across various technology sectors, including consumer internet, commercial software, and services.
What's next for A-Alpha Bio?
The recent major strategic investment, alongside previous significant capital infusions, signals A-Alpha Bio's readiness to scale its operations and advance its pipeline. This backing is expected to fuel further research and development, potentially enabling the company to move promising therapeutic candidates into clinical trials. The company's focus on a data-driven, computationally enhanced discovery process suggests a strategic expansion into new therapeutic areas and a deepening of its technological capabilities to solidify its market position in the competitive biotechnology industry.
See full A-Alpha Bio company page
